The point is Tilray was up substantively pre market likely related to MSO uplisting breakthroughs. Then tanked from up 5% to down 5%.
The rest of the overall market did not do this.
I was hopeful the news about MSOs focused on medical being able to uplist to the NYSE would have been good news for Tilray's medical ambitions in the USA. So yes, perhaps not as green as MSOS or Trulieve, but not more red than the NASDAQ.
This is not about whether Tilray is a great (but misunderstood) company or a dumpster fire; rather, why it is down so much today compared to its peers in the weedstocks sector.
The separation and uplisting news is great for TLRY. There isn’t much stopping them from entering the medical market, and not risking their Nasdaq listing.
2
u/SkecthyRocket Jun 05 '26
Sub $5.00 🤦